Beam Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to BEAM-302, its investigational therapy for alpha-1 antitrypsin deficiency (AATD)—a rare and inherited condition that affects both the lungs and liver.
AATD is caused by a genetic mutation that leads to deficient or malfunctioning alpha-1 antitrypsin (AAT) protein. This deficiency contributes to early-onset emphysema and liver disease due to the accumulation of misfolded proteins. Approximately 100,000 individuals in the U.S. have the PiZZ genotype (two copies of the Z allele), though only 10% are diagnosed.
Current treatments, such as intravenous AAT protein replacement, offer limited benefit and do not prevent long-term organ damage.
BEAM-302 is a next-generation genetic therapy designed to correct the PiZ mutation, the most common and severe form of AATD. Using an adenine base editor, BEAM-302 aims to convert a single A nucleotide to a G at the gene’s native locus—correcting the disease-causing mutation at its source.
By addressing the genetic root of AATD, BEAM-302 may provide a durable therapeutic effect, surpassing the temporary benefits of protein replacement therapy.
In addition to orphan drug designation, BEAM-302 has achieved two key regulatory designations in 2025:
These designations support the drug’s clinical development and highlight its potential to address a significant unmet medical need.
The FDA’s orphan drug designation provides several incentives for the development of therapies targeting rare diseases, including:
BEAM-302 is currently advancing through preclinical and early clinical development phases. As a precision genetic therapy, it represents a potentially transformative approach for patients with AATD—offering hope for a long-lasting and meaningful improvement in both liver and lung function.
Beam Therapeutics continues to pioneer base editing approaches across a range of severe genetic diseases, with BEAM-302 now standing as one of its most advanced and promising programs.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!